ORGO - Organogenesis gains the most in over a year after strong Q4 earnings beat

Organogenesis (ORGO +22.4%) a regenerative medicine company based in Canton, Massachusetts, has recorded the biggest intra-day gain since January 2021 on Wednesday after reporting better than expected financials for Q4 2021 with a strong earnings beat. “We delivered strong fourth-quarter financial results rounding out another transformative year for the Company,” Chief Executive Gary S. Gillheeney, Sr. remarked. Net revenue for the quarter climbed ~20% YoY to $128.6M, driven by ~30% YoY growth in Advanced Wound Care products that generated $121.4M, while net revenue from Surgical & Sports Medicine contracted ~45% YoY to $7.2M. For the full year, net revenue surged ~38% YoY to $468.1M as Advanced Wound Care added ~46% YoY to $430.8M while Surgical & Sports Medicine yielded $37.2M of net revenue with a decline of ~15% YoY. Meanwhile, the net income for Q4 and 2021 climbed ~183% YoY and ~451% YoY to $51.7M and $94.9M despite a ~26%

For further details see:

Organogenesis gains the most in over a year after strong Q4 earnings beat